首页 | 本学科首页   官方微博 | 高级检索  
检索        


Re-treatment with radium-223: 2-year follow-up from an international,open-label,phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases
Authors:Oliver Sartor MD  Daniel Heinrich MD  Neil Mariados MD  Maria José Méndez Vidal MD  Daniel Keizman MD  Camilla Thellenberg Karlsson MD  Avivit Peer MD  Giuseppe Procopio MD  Stephen J Frank MD  Kalevi Pulkkanen MD  Eli Rosenbaum MD  Stefano Severi MD  José Trigo MD  Lucia Trandafir MD  Volker Wagner MD  Rui Li MS  Luke T Nordquist MD
Institution:1. Departments of Medicine and Urology, Tulane Cancer Center, New Orleans, Louisiana;2. Department of Oncology, Akershus University Hospital, Lørenskog, Norway;3. Department of Radiation Oncology, Associated Medical Professionals of New York, PLLC, Syracuse, New York;4. Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina So?a Hospital, University of Cordoba, Cordoba, Spain;5. Genitourinary Oncology Unit, Meir Medical Center, Kfar-Saba, and Sackler School of Medicine, Tel 6. Aviv University, Tel Aviv, Israel;7. Department of Radiation Sciences, Cancer Center Norrlands University, Umeå, Sweden;8. Division of Oncology, Rambam Health Care Campus, Haifa, Israel;9. Division of Medical Oncology, Fondazione Istituto Nazionale Tumori Oncologia Medica Genitourinaria, Milan, Italy;10. Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel;11. Department of Oncology, Kuopio University Hospital, Kuopio, Finland;12. Uro-Oncology Unit, Rabin Medical Center, Davidoff Center, Petah Tikva, Israel;13. Nuclear Medicine Therapeutic Unit, Romagnolo Scienti?c Institute for the Study and Care of Cancer, IRST IRCCS, Meldola, Italy;14. Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain;15. Global Clinical Development, Bayer Pharma AG, Basel, Switzerland;16. Global Research and Development Statistics, Bayer HealthCare Pharmaceuticals, Whippany, New Jersey;17. Department of Medical Oncology, GU Research Network, LLC, Omaha, Nebraska
Abstract:
Keywords:alkaline phosphatase  prostate-specific antigen  safety  SSEs  survival  symptomatic skeletal events
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号